Dicloxacillin Suspension

Dicloxacillin Suspension

Form: Powder for Oral Suspension

Strength: 125 mg/5 mL, 250 mg/5 mL

Reference Brands: Dynapen(US)

Category: Antibiotics

Dicloxacillin suspension is approved in the EU and US for treating penicillinase-producing staphylococcal infections, particularly in children. In the EU, brands are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality standards. In the US, FDA approval relies on comprehensive clinical data, with generics available. Both regions require detailed dossiers and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for dicloxacillin suspension, ensuring adherence to European and American standards for safe, effective antibiotic therapy, especially for pediatric bacterial infections.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Fosfomycin IV

Strength: 2 g, 4g per vial

Form: Intravenous (IV)

Reference Brands: Zyflo(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience on our website. Learn more